These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38118388)

  • 21. A systematic review of prothrombin complex concentrate dosing strategies to reverse vitamin K antagonist therapy.
    Khorsand N; Kooistra HA; van Hest RM; Veeger NJ; Meijer K
    Thromb Res; 2015 Jan; 135(1):9-19. PubMed ID: 25480313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes of 4-factor Prothrombin Complex Concentrate in Patients With Liver Disease and Nonvitamin K Antagonist-Related Coagulopathy: A Retrospective Study.
    Dodhiawala PB; Pribyl K; Larson J; Vakayil V; Chandrashekar M; Lord A; Welbig J; Zantek ND; Martin D; Harmon JV
    Clin Appl Thromb Hemost; 2023; 29():10760296231198038. PubMed ID: 37649304
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dosing of 3-factor prothrombin complex concentrate for international normalized ratio reversal.
    Baggs JH; Patanwala AE; Williams EM; Erstad BL
    Ann Pharmacother; 2012 Jan; 46(1):51-6. PubMed ID: 22190253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Propensity score adjusted comparison of three-factor versus four-factor prothrombin complex concentrate for emergent warfarin reversal: a retrospective cohort study.
    Margraf DJ; Seaburg S; Beilman GJ; Wolfson J; Gipson JC; Chapman SA
    BMC Emerg Med; 2020 Nov; 20(1):93. PubMed ID: 33243152
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of prothrombin complex concentrate for vitamin K antagonist-associated intracranial hemorrhage: a systematic review and meta-analysis.
    Pan R; Cheng J; Lai K; Huang Q; Wu H; Tang Y
    Neurol Sci; 2019 Apr; 40(4):813-827. PubMed ID: 30689075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. INR and vitamin K-dependent factor levels after vitamin K antagonist reversal with 4F-PCC or plasma.
    Hood C; Goldstein JN; Milling TJ; Refaai MA; Bajcic P; Goldstein B; Sarode R
    Blood Adv; 2023 May; 7(10):2206-2213. PubMed ID: 36574241
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of Fixed-Dose Four-Factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal in Patients with Intracranial Hemorrhage.
    Scott R; Kersten B; Basior J; Nadler M
    J Emerg Med; 2018 Jun; 54(6):861-866. PubMed ID: 29510892
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and effectiveness of a prothrombin complex concentrate in approved and off-label indications.
    Marcos-Jubilar M; García Erce JA; Martínez-Calle N; Páramo JA; Martínez Virto A; Quintana-Díaz M
    Transfus Med; 2019 Aug; 29(4):268-274. PubMed ID: 31347218
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vitamin K antagonist reversal strategies: Systematic review and network meta-analysis from the AABB.
    Pagano MB; Foroutan F; Goel R; Allen ES; Cushing MM; Garcia DA; Hopkins CK; Klein K; Raval JS; Cohn CS
    Transfusion; 2022 Aug; 62(8):1652-1661. PubMed ID: 35834523
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fixed versus variable dose of prothrombin complex concentrate for counteracting vitamin K antagonist therapy.
    Khorsand N; Veeger NJ; Muller M; Overdiek JW; Huisman W; van Hest RM; Meijer K
    Transfus Med; 2011 Apr; 21(2):116-23. PubMed ID: 21073580
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emergent Warfarin Reversal With Fixed-Dose 4-Factor Prothrombin Complex Concentrate.
    Jansma B; Montgomery J; Dietrich S; Mixon MA; Peksa GD; Faine B
    Ann Pharmacother; 2020 Nov; 54(11):1090-1095. PubMed ID: 32418445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the safety and efficacy between 3-factor and 4-factor prothrombin complex concentrates for the reversal of warfarin.
    Kuroski JE; Young S
    Am J Emerg Med; 2017 Jun; 35(6):871-874. PubMed ID: 28161220
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of 3 Different Prothrombin Complex Concentrate Regimens for Emergent Warfarin Reversal: PCCWaR Study.
    Dietrich SK; Rowe S; Cocchio CA; Harmon AJ; Nerenberg SF; Blankenship PS
    Ann Pharmacother; 2021 Aug; 55(8):980-987. PubMed ID: 33305592
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and Efficacy of Warfarin Reversal with Four-Factor Prothrombin Complex Concentrate for Subtherapeutic INR in Intracerebral Hemorrhage.
    Rivosecchi RM; Durkin J; Okonkwo DO; Molyneaux BJ
    Neurocrit Care; 2016 Dec; 25(3):359-364. PubMed ID: 27076286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of Warfarin Reversal with 4-Factor Prothrombin Complex Concentrate Compared to 3-Factor Prothrombin Complex Concentrate at a Tertiary Academic Medical Center.
    Al-Majzoub O; Rybak E; Reardon DP; Krause P; Connors JM
    J Emerg Med; 2016 Jan; 50(1):7-13. PubMed ID: 26433428
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High versus low fixed-dose four factor-prothrombin complex concentrate for warfarin reversal in patients with intracranial hemorrhage.
    Compton F; Hall J; De Simone N; Usmani A; Sarode R; Burner J
    Transfus Apher Sci; 2022 Oct; 61(5):103444. PubMed ID: 35414467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inactivated Four-Factor Prothrombin Complex Concentrate Dosing Practices for Reversal of Warfarin-Related Intracranial Hemorrhage.
    Rhoney DH; La M; Merz M; Cook A; Owusu KA; Roels C; Blunck J; Shewmaker J; Sangha KS; Farrokh S; Lewin J; Chester KW; Human T; Bledsoe K; Greene K; Levesque M; Rocker JC; Davis G; Neyens R; Lassiter TF; Adriance SM
    Neurocrit Care; 2021 Aug; 35(1):130-138. PubMed ID: 33219462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of 3-factor versus 4-factor prothrombin complex concentrate for emergent warfarin reversal: a systematic review and meta-analysis.
    Margraf DJ; Brown SJ; Blue HL; Bezdicek TL; Wolfson J; Chapman SA
    BMC Emerg Med; 2022 Jan; 22(1):14. PubMed ID: 35073849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An international, multicenter, prospective study of a prothrombin complex concentrate, Prothromplex Total®, in anticoagulant reversal.
    Altorjay Á; Szabó É; Boda Z; Kramer L; Ngo LY; Engl W; Firth CL; Ahlstrom ER; Gelmont DM; Pabinger I
    Thromb Res; 2015 Mar; 135(3):485-91. PubMed ID: 25613927
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prothrombin complex concentrate versus standard therapies for INR reversal in trauma patients receiving warfarin.
    Chapman SA; Irwin ED; Beal AL; Kulinski NM; Hutson KE; Thorson MA
    Ann Pharmacother; 2011 Jul; 45(7-8):869-75. PubMed ID: 21775690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.